

8 August 2014

Jibon Health Technologies, Inc. and Partner NGO icddr, b Awarded a 2014 Saving Lives at Birth: A Grand Challenge for Development Seed Grant

Washington, DC, USA – New York City and Bangladesh-based startup Jibon Health Technologies, Inc., along with their partner NGO icddr, b, are pleased to announce that they have been awarded a 2014 Saving Lives at Birth: A Grand Challenge for Development seed grant in order to conduct Phase I and II clinical trials of Tampostat, a low-cost, self-regulating emergency obstetric device for the treatment of postpartum hemorrhage.

Saving Lives at Birth: A Grand Challenge for Development awarded 22 seed grants this year from a pool of over 2,000 applicants from over 150 countries. The grant is sponsored by USAID, the Norwegian Ministry of Foreign Affairs, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and UKAID.

This \$250,000 grant will fund Phase I and Phase II clinical trials of Tampostat in Bangladesh over a period of two years. The clinical trials will be conducted and overseen by icddr, b and key members of the Jibon Health Technologies, Inc. managing team and medical advisory board.

About Jibon Health Technologies, Inc.

Jibon Health Technologies, Inc. was founded by a group of young professionals driven to solve global health problems through creative engineering. Their first medical device, Tampostat™, is a simple and low-cost emergency medical device used to treat postpartum hemorrhage in the developing world. PPH the leading cause of maternal mortality worldwide, affects 14 million women and claims 150,000 lives annually. 99% of deaths occur in low-resource settings, where the majority of women give birth at home. This is due to a lack of available resources and training for midwives performing home deliveries, as most current PPH treatment options can only be administered by higher-level health workers in a hospital setting—often hours away from the patient's home. Tampostat was designed specifically for use by midwives at the community level and is currently undergoing pilot testing in Bangladesh.

Contact

Mikail Kamal, Chief Executive Officer
Jibon Health Technologies, Inc.
(m) +1 (646) 361-7977
(e) mikail@jibonhealth.com

Visit www.jibonhealth.com to learn more